These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24560278)

  • 1. The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis.
    Dias PCS; Sena-Evangelista KCM; Paiva MSMO; Ferreira DQC; Ururahy MAG; Rezende AA; Abdalla DSP; Pedrosa LFC
    J Trace Elem Med Biol; 2014 Apr; 28(2):194-199. PubMed ID: 24560278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study.
    Sena-Evangelista KC; Pedrosa LF; Paiva MS; Dias PC; Ferreira DQ; Cozzolino SM; Faulin TE; Abdalla DS
    PLoS One; 2015; 10(3):e0119830. PubMed ID: 25785441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
    Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
    Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis.
    Liu B; Cao HM; Li GY; Liu M; Feng J; Li J; Wang Q
    J Int Med Res; 2011; 39(6):2314-22. PubMed ID: 22289549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
    Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
    Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
    Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P
    Curr Med Res Opin; 2011 Jun; 27(6):1119-29. PubMed ID: 21446892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
    Funderburg NT; Jiang Y; Debanne SM; Storer N; Labbato D; Clagett B; Robinson J; Lederman MM; McComsey GA
    Clin Infect Dis; 2014 Feb; 58(4):588-95. PubMed ID: 24253250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial.
    Mok CC; Wong CK; To CH; Lai JP; Lam CS
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):875-83. PubMed ID: 21309005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).
    ter Avest E; Abbink EJ; Holewijn S; de Graaf J; Tack CJ; Stalenhoef AF
    Curr Med Res Opin; 2005 Sep; 21(9):1469-76. PubMed ID: 16197666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.